taRgeting bEtA-Cell Function To achIeVe Remission of Type 2 diAbeTEs

Not Applicable

Recruiting

• Conditions: Type 2 Diabetes

• Registration Number: NCT06844539
• Lead Sponsor: University of Cambridge

Brief Summary

The main objective of the REACTIVATE study is to investigate whether a period of intensive insulin therapy using closed-loop technology, when combined with diet and lifestyle education, can restore beta-cell function and achieve remission of recent-onset type 2 diabetes.

This is a single-centre, open-label, randomised, parallel design study comparing up to 12 weeks of fully closed-loop insulin delivery to standard care with a glucose sensor in adults with recent-onset type 2 diabetes. The primary outcome is the number of participants achieving remission of diabetes at 52 weeks, defined as HbA1c below 48mmol/mol after 12 or more weeks off all diabetes medications.

Other key outcomes include area under the curve for C-peptide and glucose during mixed meal tolerance test, the proportion of time spent with glucose levels within and above the target glucose range and mean sensor glucose as recorded by glucose sensor at 52 weeks.

Safety evaluation comprises severe hypoglycaemic episodes, and other adverse and serious adverse events. Utility and human factors outcomes include glucose sensor and closed-loop usage, questionnaires and semi-structured interviews.

Detailed Description

This is a single-centre, open-label, randomised, parallel design study comparing up to 12 weeks of fully closed-loop insulin delivery to standard care with a glucose sensor in adults with recent-onset type 2 diabetes.

Recruitment will target up to 56 participants to allow for drop-outs. Participants will be recruited from outpatient clinics at Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, local GP surgeries, social media advertising or other established practices at the centre. Written informed consent will be obtained from all participants before any study related activities.

After obtaining informed consent, the baseline visit (including mixed meal tolerance test) and a 2-3 week run-in period, participants will be randomised to either 12 weeks use of fully closed-loop insulin delivery or 12 weeks during which they will apply their standard diabetes therapy with a glucose sensor. Participants in both groups will receive diet and lifestyle advice with specific focus on the impact of diet and lifestyle choices on glucose sensor readings and trends.

Following the 12 weeks intervention period (and repeat mixed meal tolerance test) all participants will continue with standard diabetes therapy for nine months of follow-up (and final mixed meal tolerance test). Diabetes therapies will be adjusted every 3 months based on HbA1c.

The study includes up to 5 visits and 6 telephone/email contacts. Visits 2 and 3 may be combined. All participants will continue to be seen by their clinical team at frequencies as appropriate in line with usual clinical practice. All study visits will be scheduled in addition to routine clinical visits and will be performed by the research team. Maximum time in the study is 56 weeks.

Study Timeline

• Status Verified: 2025-02
• Study First Submitted: 2025-02-19
• Study First Submitted QC: 2025-02-24
• Study First Posted: 2025-03-25
• Last Update Submitted: 2025-03-27
• Last Update Posted: 2025-03-28
• Study Start: 2025-04-24
• Primary Completion: 2028-12-31
• Study Completion: 2029-04-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

• Aged 18 years and older
• Type 2 diabetes diagnosed >6 months and ≤5 years ago
• Treatment with glucose lowering medication for at least 3 months
• HbA1c >48 mmol/mol on analysis from local laboratory or equivalent
• Willing to wear study devices and follow study instructions
• Capacity to consent to participate in the study

Exclusion Criteria

• Type 1 diabetes
• Current use of insulin pump
• Current use of any closed-loop system
• Any physical/psychological disease or medication(s) likely to interfere with the conduct of the study and interpretation of the study results, as judged by study clinician
• Known or suspected allergy against insulin
• Pregnancy, planned pregnancy, or breast feeding
• Severe visual or hearing impairment
• Medically documented allergy towards the adhesive of plasters
• Serious skin diseases located at places of the body potentially used for localisation of the glucose sensor
• Drug or alcohol misuse
• Group 2 driving licence holder

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
The number of participants achieving remission of diabetes at 52 weeks	52 weeks	The between group difference in the number of participants achieving remission of diabetes at 52 weeks, defined as HbA1c \<48mmol/mol after ≥12 weeks off all diabetes medications.

Secondary Outcome Measures

Name	Time	Method
Mixed meal tolerance test (MMTT) area under the curve for C-peptide	52 weeks	Mixed meal tolerance test (MMTT) area under the curve for C-peptide
Proportion of time spent intarget glucose range (3.9 to 10.0mmol/l)	52 weeks	Proportion of time spent with sensor glucose in target glucose range (3.9 to 10.0mmol/l)
Mixed meal tolerance test (MMTT) area under the curve for glucose	52 weeks	Mixed meal tolerance test (MMTT) area under the curve for glucose
Proportion of time spent in tight target glucose range (3.9 to 7.8mmol/l)	52 weeks	Proportion of time spent with sensor glucose in tight target glucose range (3.9 to 7.8mmol/l)
Proportion of time spent in target glucose range (3.9 to 10.0mmol/l)	12 weeks	Proportion of time spent with sensor glucose in target glucose range (3.9 to 10.0mmol/l)
Proportion of time spent below target glucose range (<3.9mmol/l)	52 weeks	Proportion of time spent below target glucose range (\<3.9mmol/l)
Number of diabetes medications	52 weeks	Number of diabetes medications
Proportion of time spent above target glucose range (>10.0mmol/l)	52 weeks	Proportion of time spent above target glucose range (\>10.0mmol/l)
Blood pressure	52 weeks	Blood pressure (mmHg)
Mean sensor glucose	52 weeks	Mean sensor glucose (mmol/l)
Glycated haemoglobin	52 weeks	HbA1c (mmol/mol)
Body weight	52 weeks	Body weight (kg)

Trial Locations

Locations (1)

Addenbrooke's Hospital NHS Foundation Trust; 🇬🇧 Cambridge, Cambridgeshire, United Kingdom